Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity. For more information, please email info@tizonatx.com.